Cidofovir (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Cidofovir" in English language version.

refsWebsite

Global rank English rank

20nih.gov

4^th place

15doi.org

2^nd place

7semanticscholar.org

11^th place

8^th place

3gilead.com

low place

2web.archive.org

1^st place

1fda.gov

447^th place

338^th place

1canada.ca

1,712^th place

1,063^rd place

1medscape.com

719^th place

636^th place

1tga.gov.au

3,984^th place

2,622^nd place

1books.google.com

3^rd place

1drugs.com

399^th place

333^rd place

1europa.eu

68^th place

117^th place

1cdc.gov

218^th place

212^th place

books.google.com

Long SS, Prober CG, Fischer M (2012). Principles and Practice of Pediatric Infectious Disease. Elsevier Health Sciences. p. 1502. ISBN 978-1437727029.

canada.ca

"Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada. 14 October 2020. Retrieved 17 April 2024.

cdc.gov

"Interim Clinical Guidance for the Treatment of Monkeypox". U.S. Centers for Disease Control and Prevention. 26 May 2022.

doi.org

Chilukuri S, Rosen T (April 2003). "Management of acyclovir-resistant herpes simplex virus". Dermatologic Clinics. 21 (2): 311–320. doi:10.1016/S0733-8635(02)00093-1. PMID 12757254.
Segarra-Newnham M, Vodolo KM (June 2001). "Use of cidofovir in progressive multifocal leukoencephalopathy". The Annals of Pharmacotherapy. 35 (6): 741–744. doi:10.1345/aph.10338. PMID 11408993. S2CID 32026770.^{[permanent dead link‍]}
De Gascun CF, Carr MJ (2013). "Human polyomavirus reactivation: disease pathogenesis and treatment approaches". Clinical & Developmental Immunology. 2013: 373579. doi:10.1155/2013/373579. PMC 3659475. PMID 23737811.
De Clercq E (July 2002). "Cidofovir in the treatment of poxvirus infections". Antiviral Research. 55 (1): 1–13. doi:10.1016/S0166-3542(02)00008-6. PMC 9533828. PMID 12076747.
Bradbury J (March 2002). "Orally available cidofovir derivative active against smallpox". Lancet. 359 (9311): 1041. doi:10.1016/S0140-6736(02)08115-1. PMID 11937193. S2CID 22903225.
Magee WC, Hostetler KY, Evans DH (August 2005). "Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate". Antimicrobial Agents and Chemotherapy. 49 (8): 3153–3162. doi:10.1128/AAC.49.8.3153-3162.2005. PMC 1196213. PMID 16048917.
Araya CE, Lew JF, Fennell RS, Neiberger RE, Dharnidharka VR (February 2006). "Intermediate-dose cidofovir without probenecid in the treatment of BK virus allograft nephropathy". Pediatric Transplantation. 10 (1): 32–37. doi:10.1111/j.1399-3046.2005.00391.x. PMID 16499584. S2CID 24131709.
Broekema FI, Dikkers FG (August 2008). "Side-effects of cidofovir in the treatment of recurrent respiratory papillomatosis". European Archives of Oto-Rhino-Laryngology. 265 (8): 871–879. doi:10.1007/s00405-008-0658-0. PMC 2441494. PMID 18458927.
Soma MA, Albert DM (February 2008). "Cidofovir: to use or not to use?". Current Opinion in Otolaryngology & Head and Neck Surgery. 16 (1): 86–90. doi:10.1097/MOO.0b013e3282f43408. PMID 18197029. S2CID 22895067.
Fernández-Morano T, del Boz J, González-Carrascosa M, Tortajada B, de Troya M (December 2011). "Topical cidofovir for viral warts in children". Journal of the European Academy of Dermatology and Venereology. 25 (12): 1487–1489. doi:10.1111/j.1468-3083.2010.03961.x. PMID 21261749. S2CID 32295082.
Kern ER (January 2003). "In vitro activity of potential anti-poxvirus agents". Antiviral Research. 57 (1–2): 35–40. doi:10.1016/s0166-3542(02)00198-5. PMC 9628899. PMID 12615301. S2CID 23136929.
Andrei G, Snoeck R (December 2010). "Cidofovir Activity against Poxvirus Infections". Viruses. 2 (12): 2803–2830. doi:10.3390/v2122803. PMC 3185586. PMID 21994641.
Lacy SA, Hitchcock MJ, Lee WA, Tellier P, Cundy KC (August 1998). "Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys". Toxicological Sciences. 44 (2): 97–106. doi:10.1006/toxs.1998.2481. PMID 9742650.
Safrin S, Cherrington J, Jaffe HS (September 1997). "Clinical uses of cidofovir". Reviews in Medical Virology. 7 (3): 145–156. doi:10.1002/(SICI)1099-1654(199709)7:3<145::AID-RMV196>3.0.CO;2-0. PMID 10398479. S2CID 32366514.
Brodfuehrer PR, Howell HG, Sapino Jr C, Vemishetti P (1994). "A practical synthesis of (S)-HPMPC". Tetrahedron Letters. 35 (20): 3243. doi:10.1016/S0040-4039(00)76875-4.

drugs.com

"Cidofovir Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 5 February 2014.

europa.eu

ema.europa.eu

"Vistide : EPAR – Product Information" (PDF). European Medicines Agency. Gilead Sciences International Ltd. 7 November 2013. Archived from the original (PDF) on 22 February 2014. Retrieved 5 February 2014.

fda.gov

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.

gilead.com

"Details" (PDF). www.gilead.com. Retrieved 2019-06-05.
"Vistide (cidofovir)" (PDF) (package insert). Gilead Sciences. September 2010. Dosage and Administration: Dosage.
"Press Releases: Gilead". Archived from the original on 2013-02-08. Retrieved 2007-12-05.

medscape.com

reference.medscape.com

"Vistide (cidofovir) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 4 February 2014.

nih.gov

pubmed.ncbi.nlm.nih.gov

Chilukuri S, Rosen T (April 2003). "Management of acyclovir-resistant herpes simplex virus". Dermatologic Clinics. 21 (2): 311–320. doi:10.1016/S0733-8635(02)00093-1. PMID 12757254.
Segarra-Newnham M, Vodolo KM (June 2001). "Use of cidofovir in progressive multifocal leukoencephalopathy". The Annals of Pharmacotherapy. 35 (6): 741–744. doi:10.1345/aph.10338. PMID 11408993. S2CID 32026770.^{[permanent dead link‍]}
De Gascun CF, Carr MJ (2013). "Human polyomavirus reactivation: disease pathogenesis and treatment approaches". Clinical & Developmental Immunology. 2013: 373579. doi:10.1155/2013/373579. PMC 3659475. PMID 23737811.
De Clercq E (July 2002). "Cidofovir in the treatment of poxvirus infections". Antiviral Research. 55 (1): 1–13. doi:10.1016/S0166-3542(02)00008-6. PMC 9533828. PMID 12076747.
Bradbury J (March 2002). "Orally available cidofovir derivative active against smallpox". Lancet. 359 (9311): 1041. doi:10.1016/S0140-6736(02)08115-1. PMID 11937193. S2CID 22903225.
Magee WC, Hostetler KY, Evans DH (August 2005). "Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate". Antimicrobial Agents and Chemotherapy. 49 (8): 3153–3162. doi:10.1128/AAC.49.8.3153-3162.2005. PMC 1196213. PMID 16048917.
Araya CE, Lew JF, Fennell RS, Neiberger RE, Dharnidharka VR (February 2006). "Intermediate-dose cidofovir without probenecid in the treatment of BK virus allograft nephropathy". Pediatric Transplantation. 10 (1): 32–37. doi:10.1111/j.1399-3046.2005.00391.x. PMID 16499584. S2CID 24131709.
Broekema FI, Dikkers FG (August 2008). "Side-effects of cidofovir in the treatment of recurrent respiratory papillomatosis". European Archives of Oto-Rhino-Laryngology. 265 (8): 871–879. doi:10.1007/s00405-008-0658-0. PMC 2441494. PMID 18458927.
Soma MA, Albert DM (February 2008). "Cidofovir: to use or not to use?". Current Opinion in Otolaryngology & Head and Neck Surgery. 16 (1): 86–90. doi:10.1097/MOO.0b013e3282f43408. PMID 18197029. S2CID 22895067.
Fernández-Morano T, del Boz J, González-Carrascosa M, Tortajada B, de Troya M (December 2011). "Topical cidofovir for viral warts in children". Journal of the European Academy of Dermatology and Venereology. 25 (12): 1487–1489. doi:10.1111/j.1468-3083.2010.03961.x. PMID 21261749. S2CID 32295082.
Kern ER (January 2003). "In vitro activity of potential anti-poxvirus agents". Antiviral Research. 57 (1–2): 35–40. doi:10.1016/s0166-3542(02)00198-5. PMC 9628899. PMID 12615301. S2CID 23136929.
Andrei G, Snoeck R (December 2010). "Cidofovir Activity against Poxvirus Infections". Viruses. 2 (12): 2803–2830. doi:10.3390/v2122803. PMC 3185586. PMID 21994641.
Lacy SA, Hitchcock MJ, Lee WA, Tellier P, Cundy KC (August 1998). "Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys". Toxicological Sciences. 44 (2): 97–106. doi:10.1006/toxs.1998.2481. PMID 9742650.
Safrin S, Cherrington J, Jaffe HS (September 1997). "Clinical uses of cidofovir". Reviews in Medical Virology. 7 (3): 145–156. doi:10.1002/(SICI)1099-1654(199709)7:3<145::AID-RMV196>3.0.CO;2-0. PMID 10398479. S2CID 32366514.

ncbi.nlm.nih.gov

De Gascun CF, Carr MJ (2013). "Human polyomavirus reactivation: disease pathogenesis and treatment approaches". Clinical & Developmental Immunology. 2013: 373579. doi:10.1155/2013/373579. PMC 3659475. PMID 23737811.
De Clercq E (July 2002). "Cidofovir in the treatment of poxvirus infections". Antiviral Research. 55 (1): 1–13. doi:10.1016/S0166-3542(02)00008-6. PMC 9533828. PMID 12076747.
Magee WC, Hostetler KY, Evans DH (August 2005). "Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate". Antimicrobial Agents and Chemotherapy. 49 (8): 3153–3162. doi:10.1128/AAC.49.8.3153-3162.2005. PMC 1196213. PMID 16048917.
Broekema FI, Dikkers FG (August 2008). "Side-effects of cidofovir in the treatment of recurrent respiratory papillomatosis". European Archives of Oto-Rhino-Laryngology. 265 (8): 871–879. doi:10.1007/s00405-008-0658-0. PMC 2441494. PMID 18458927.
Kern ER (January 2003). "In vitro activity of potential anti-poxvirus agents". Antiviral Research. 57 (1–2): 35–40. doi:10.1016/s0166-3542(02)00198-5. PMC 9628899. PMID 12615301. S2CID 23136929.
Andrei G, Snoeck R (December 2010). "Cidofovir Activity against Poxvirus Infections". Viruses. 2 (12): 2803–2830. doi:10.3390/v2122803. PMC 3185586. PMID 21994641.

semanticscholar.org

api.semanticscholar.org

Segarra-Newnham M, Vodolo KM (June 2001). "Use of cidofovir in progressive multifocal leukoencephalopathy". The Annals of Pharmacotherapy. 35 (6): 741–744. doi:10.1345/aph.10338. PMID 11408993. S2CID 32026770.^{[permanent dead link‍]}
Bradbury J (March 2002). "Orally available cidofovir derivative active against smallpox". Lancet. 359 (9311): 1041. doi:10.1016/S0140-6736(02)08115-1. PMID 11937193. S2CID 22903225.
Araya CE, Lew JF, Fennell RS, Neiberger RE, Dharnidharka VR (February 2006). "Intermediate-dose cidofovir without probenecid in the treatment of BK virus allograft nephropathy". Pediatric Transplantation. 10 (1): 32–37. doi:10.1111/j.1399-3046.2005.00391.x. PMID 16499584. S2CID 24131709.
Soma MA, Albert DM (February 2008). "Cidofovir: to use or not to use?". Current Opinion in Otolaryngology & Head and Neck Surgery. 16 (1): 86–90. doi:10.1097/MOO.0b013e3282f43408. PMID 18197029. S2CID 22895067.
Fernández-Morano T, del Boz J, González-Carrascosa M, Tortajada B, de Troya M (December 2011). "Topical cidofovir for viral warts in children". Journal of the European Academy of Dermatology and Venereology. 25 (12): 1487–1489. doi:10.1111/j.1468-3083.2010.03961.x. PMID 21261749. S2CID 32295082.
Kern ER (January 2003). "In vitro activity of potential anti-poxvirus agents". Antiviral Research. 57 (1–2): 35–40. doi:10.1016/s0166-3542(02)00198-5. PMC 9628899. PMID 12615301. S2CID 23136929.
Safrin S, Cherrington J, Jaffe HS (September 1997). "Clinical uses of cidofovir". Reviews in Medical Virology. 7 (3): 145–156. doi:10.1002/(SICI)1099-1654(199709)7:3<145::AID-RMV196>3.0.CO;2-0. PMID 10398479. S2CID 32366514.

tga.gov.au

ebs.tga.gov.au

"Product Information VISTIDE®". TGA eBusiness Services. Gilead Sciences Pty Ltd. 3 September 2013. Retrieved 5 February 2014.

web.archive.org

"Vistide : EPAR – Product Information" (PDF). European Medicines Agency. Gilead Sciences International Ltd. 7 November 2013. Archived from the original (PDF) on 22 February 2014. Retrieved 5 February 2014.
"Press Releases: Gilead". Archived from the original on 2013-02-08. Retrieved 2007-12-05.